Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Enlivex Therapeutics Ltd.

Enlivex Therapeutics ($ENLV) announced an update on their ongoing clinical study. This Phase IIb study, titled “A Phase IIb, Randomized, Double-Bli...

Enlivex Advances Allocetra Into Mid-Stage Knee Osteoarthritis Trial, Keeping Investor Focus on ENLV

Enlivex ( ($ENLV) ) has shared an update. Enlivex Ltd. is a Nasdaq-listed quality longevity company based in Israel that is advancing Allocetra™, a...

Enlivex Faces Nasdaq Minimum Bid Price Deficiency After Shares Fall Below $1 Threshold

We’ve identified three of the best cheap stocks to buy today. Price is important to us all, especially during tough economic times. That is true in...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ENLV	$0.70	-0.14%	134.62K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ENLV	$0.70	-0.1%	134.62K
3
4
5
6

ENLV

ENLV

Latest News for ENLV

Get Enlivex Therapeutics Ltd. Data in Excel

Get Enlivex Therapeutics Ltd. Data in Excel